In the study of congenital hyperinsulinism now enrolling phase III sunRIZE trial

sunrize logo

NEJM Letter to the Editor: Anti–Insulin Receptor Antibody for Malignant Insulinoma and Refractory Hypoglycemia

Back to Careers